The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.11 billion in 2023 to $8.46 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historical period can be attributed to factors such as advancements in cardiovascular medicine research, increased awareness of heart health, shifts in treatment paradigms, adherence to clinical guidelines and recommendations, and an emphasis on preventive healthcare.
The low-density lipoprotein test market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecast period can be attributed to factors such as increasing healthcare expenditure, demographic changes with an aging population, a rise in the burden of cardiovascular diseases, a shift towards personalized medicine, and the influence of healthcare policy and guidelines. Major trends expected in the forecast period include the rising prevalence of cardiovascular diseases, an emphasis on preventive healthcare, the adoption of personalized medicine and treatment approaches, a focus on health awareness and education, and the impact of regulatory guidelines and recommendations.
The anticipated increase in the prevalence of cardiovascular diseases is set to drive the growth of the low-density lipoprotein test market. Cardiovascular diseases encompass conditions affecting the heart or blood vessels, and the LDL test plays a crucial role in managing these diseases by directly measuring low-density lipoprotein levels. For example, as of October 2022, the Centers for Disease Control and Prevention (CDC) reported that heart disease ranks as the leading cause of mortality in the United States across genders and most racial and ethnic groups. Heart disease claimed nearly 695,000 lives in the United States in 2021, accounting for one in every five deaths. The most prevalent type, coronary heart disease, resulted in 375,476 deaths in 2020. Hence, the surge in cardiovascular diseases is a driving force behind the expansion of the low-density lipoprotein test market.
The increasing prevalence of obesity is expected to fuel the growth of the low-density lipoprotein test market. Obesity, characterized by excessive body fat accumulation and a body mass index (BMI) of 30 or higher, is associated with numerous health risks. The low-density lipoprotein (LDL) test is instrumental in measuring LDL cholesterol levels in individuals affected by obesity. For instance, according to the World Health Organization's March 2022 report, over 1 billion individuals globally grapple with obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with these numbers on the rise. Additionally, it is estimated that around 167 million people are poised to experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is propelling the growth of the low-density lipoprotein test market.
Product innovations are emerging as a key trend in the low-density lipoprotein test market, with major companies introducing innovative products to maintain their market position. In December 2021, Novartis AG, a Switzerland-based pharmaceutical giant, launched Leqvio (Inclisiran), a groundbreaking siRNA therapy designed to lower low-density lipoprotein cholesterol effectively. This medication offers sustained reductions in LDL cholesterol and requires only two maintenance doses annually. For certain patients with atherosclerotic cardiovascular disease (ASCVD) receiving maximally tolerated statin therapy, Leqvio delivers a substantial and long-lasting LDL cholesterol decrease of up to 52% compared to a placebo. This innovative approach opens new possibilities for impacting cardiovascular disease within healthcare systems.
Major companies in the low-density lipoprotein test market are strategically focusing on developing innovations such as homogenous assays to gain a competitive edge. A homogenous assay is an immunoassay type that does not necessitate a separation step to measure analyte concentration. For example, in May 2021, DiaSys Diagnostic Systems GmbH, a US-based developer of clinical diagnostic equipment, launched LDL-c direct FS, a homogenous assay for directly determining LDL cholesterol levels. This fast, accurate, and reliable assay employs a block-polymer-based approach, offering extended stability and low calibration frequency. It is compatible with all automated clinical chemical analyzers and exhibits strong compatibility with commercially available techniques for measuring low-density lipoprotein.
In February 2023, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, completed the acquisition of CinCor Pharma Inc. for an undisclosed amount. This strategic move is expected to bolster AstraZeneca's cardiorenal pipeline, expanding it with Baxdrostat, a novel aldosterone synthase inhibitor (ASI). CinCor Pharma Inc., a US-based clinical-last biotechnology company, specializes in developing therapies for lowering LDL hypertension.
Major companies operating in the low-density lipoprotein test market report are Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., Lincoln Diagnostics LLC, DiaSorin S.p.A., Boster Biological Technology Ltd., Rockland Immunochemicals Inc., Sekisui Diagnostics LLC, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc., Cell Biolabs Inc, Home Access Health Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Quest Diagnostics Incorporated, SpectraCell Laboratories Inc., Siemens AG, Alfa Wassermann Inc., Laboratory Corporation of America Holdings, Merck KGaA, F Hoffmann-La Roche Ltd., Agilent Technologies Inc., BioVision Incorporated, Abcam plc, BioAssay Systems, BioChain Institute Inc., BioLegend Inc., Bioo Scientific LLC, Enzo Life Sciences Inc., GenScript Biotech Corporation.
North America was the largest region in the Low-Density Lipoprotein Test market in 2023. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the low-density lipoprotein test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary product types of low-density lipoprotein tests include LDL-C, LDL-P, LDL-B, and other related products. Low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol,' tends to accumulate in the walls of blood vessels, increasing the risk of health issues such as heart attacks or strokes. The components used in these tests include kits, reagents, devices, and other related components. These tests find applications in various health conditions such as diabetes, stroke, atherosclerosis, obesity, dyslipidemia, carotid artery disease, peripheral arterial disease, angina, among others. Distribution channels encompass direct tenders and retail outlets, with usage prevalent in hospitals, clinics, ambulatory care centers, research laboratories, and other healthcare settings.
The low-density lipoprotein test market research report is one of a series of new reports that provides low-density lipoprotein test market statistics, including low-density lipoprotein test industry global market size, regional shares, competitors with a low-density lipoprotein test market share, detailed low-density lipoprotein test market segments, market trends and opportunities, and any further data you may need to thrive in the low-density lipoprotein test industry. This low-density lipoprotein test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The low-density lipoprotein test market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecast period can be attributed to factors such as increasing healthcare expenditure, demographic changes with an aging population, a rise in the burden of cardiovascular diseases, a shift towards personalized medicine, and the influence of healthcare policy and guidelines. Major trends expected in the forecast period include the rising prevalence of cardiovascular diseases, an emphasis on preventive healthcare, the adoption of personalized medicine and treatment approaches, a focus on health awareness and education, and the impact of regulatory guidelines and recommendations.
The anticipated increase in the prevalence of cardiovascular diseases is set to drive the growth of the low-density lipoprotein test market. Cardiovascular diseases encompass conditions affecting the heart or blood vessels, and the LDL test plays a crucial role in managing these diseases by directly measuring low-density lipoprotein levels. For example, as of October 2022, the Centers for Disease Control and Prevention (CDC) reported that heart disease ranks as the leading cause of mortality in the United States across genders and most racial and ethnic groups. Heart disease claimed nearly 695,000 lives in the United States in 2021, accounting for one in every five deaths. The most prevalent type, coronary heart disease, resulted in 375,476 deaths in 2020. Hence, the surge in cardiovascular diseases is a driving force behind the expansion of the low-density lipoprotein test market.
The increasing prevalence of obesity is expected to fuel the growth of the low-density lipoprotein test market. Obesity, characterized by excessive body fat accumulation and a body mass index (BMI) of 30 or higher, is associated with numerous health risks. The low-density lipoprotein (LDL) test is instrumental in measuring LDL cholesterol levels in individuals affected by obesity. For instance, according to the World Health Organization's March 2022 report, over 1 billion individuals globally grapple with obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with these numbers on the rise. Additionally, it is estimated that around 167 million people are poised to experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is propelling the growth of the low-density lipoprotein test market.
Product innovations are emerging as a key trend in the low-density lipoprotein test market, with major companies introducing innovative products to maintain their market position. In December 2021, Novartis AG, a Switzerland-based pharmaceutical giant, launched Leqvio (Inclisiran), a groundbreaking siRNA therapy designed to lower low-density lipoprotein cholesterol effectively. This medication offers sustained reductions in LDL cholesterol and requires only two maintenance doses annually. For certain patients with atherosclerotic cardiovascular disease (ASCVD) receiving maximally tolerated statin therapy, Leqvio delivers a substantial and long-lasting LDL cholesterol decrease of up to 52% compared to a placebo. This innovative approach opens new possibilities for impacting cardiovascular disease within healthcare systems.
Major companies in the low-density lipoprotein test market are strategically focusing on developing innovations such as homogenous assays to gain a competitive edge. A homogenous assay is an immunoassay type that does not necessitate a separation step to measure analyte concentration. For example, in May 2021, DiaSys Diagnostic Systems GmbH, a US-based developer of clinical diagnostic equipment, launched LDL-c direct FS, a homogenous assay for directly determining LDL cholesterol levels. This fast, accurate, and reliable assay employs a block-polymer-based approach, offering extended stability and low calibration frequency. It is compatible with all automated clinical chemical analyzers and exhibits strong compatibility with commercially available techniques for measuring low-density lipoprotein.
In February 2023, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, completed the acquisition of CinCor Pharma Inc. for an undisclosed amount. This strategic move is expected to bolster AstraZeneca's cardiorenal pipeline, expanding it with Baxdrostat, a novel aldosterone synthase inhibitor (ASI). CinCor Pharma Inc., a US-based clinical-last biotechnology company, specializes in developing therapies for lowering LDL hypertension.
Major companies operating in the low-density lipoprotein test market report are Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., Lincoln Diagnostics LLC, DiaSorin S.p.A., Boster Biological Technology Ltd., Rockland Immunochemicals Inc., Sekisui Diagnostics LLC, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc., Cell Biolabs Inc, Home Access Health Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Quest Diagnostics Incorporated, SpectraCell Laboratories Inc., Siemens AG, Alfa Wassermann Inc., Laboratory Corporation of America Holdings, Merck KGaA, F Hoffmann-La Roche Ltd., Agilent Technologies Inc., BioVision Incorporated, Abcam plc, BioAssay Systems, BioChain Institute Inc., BioLegend Inc., Bioo Scientific LLC, Enzo Life Sciences Inc., GenScript Biotech Corporation.
North America was the largest region in the Low-Density Lipoprotein Test market in 2023. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the low-density lipoprotein test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary product types of low-density lipoprotein tests include LDL-C, LDL-P, LDL-B, and other related products. Low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol,' tends to accumulate in the walls of blood vessels, increasing the risk of health issues such as heart attacks or strokes. The components used in these tests include kits, reagents, devices, and other related components. These tests find applications in various health conditions such as diabetes, stroke, atherosclerosis, obesity, dyslipidemia, carotid artery disease, peripheral arterial disease, angina, among others. Distribution channels encompass direct tenders and retail outlets, with usage prevalent in hospitals, clinics, ambulatory care centers, research laboratories, and other healthcare settings.
The low-density lipoprotein test market research report is one of a series of new reports that provides low-density lipoprotein test market statistics, including low-density lipoprotein test industry global market size, regional shares, competitors with a low-density lipoprotein test market share, detailed low-density lipoprotein test market segments, market trends and opportunities, and any further data you may need to thrive in the low-density lipoprotein test industry. This low-density lipoprotein test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Low-Density Lipoprotein Test Market Characteristics3. Low-Density Lipoprotein Test Market Trends and Strategies31. Global Low-Density Lipoprotein Test Market Competitive Benchmarking32. Global Low-Density Lipoprotein Test Market Competitive Dashboard33. Key Mergers and Acquisitions in the Low-Density Lipoprotein Test Market
4. Low-Density Lipoprotein Test Market - Macro Economic Scenario
5. Global Low-Density Lipoprotein Test Market Size and Growth
6. Low-Density Lipoprotein Test Market Segmentation
7. Low-Density Lipoprotein Test Market Regional and Country Analysis
8. Asia-Pacific Low-Density Lipoprotein Test Market
9. China Low-Density Lipoprotein Test Market
10. India Low-Density Lipoprotein Test Market
11. Japan Low-Density Lipoprotein Test Market
12. Australia Low-Density Lipoprotein Test Market
13. Indonesia Low-Density Lipoprotein Test Market
14. South Korea Low-Density Lipoprotein Test Market
15. Western Europe Low-Density Lipoprotein Test Market
16. UK Low-Density Lipoprotein Test Market
17. Germany Low-Density Lipoprotein Test Market
18. France Low-Density Lipoprotein Test Market
19. Italy Low-Density Lipoprotein Test Market
20. Spain Low-Density Lipoprotein Test Market
21. Eastern Europe Low-Density Lipoprotein Test Market
22. Russia Low-Density Lipoprotein Test Market
23. North America Low-Density Lipoprotein Test Market
24. USA Low-Density Lipoprotein Test Market
25. Canada Low-Density Lipoprotein Test Market
26. South America Low-Density Lipoprotein Test Market
27. Brazil Low-Density Lipoprotein Test Market
28. Middle East Low-Density Lipoprotein Test Market
29. Africa Low-Density Lipoprotein Test Market
30. Low-Density Lipoprotein Test Market Competitive Landscape and Company Profiles
34. Low-Density Lipoprotein Test Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Low-Density Lipoprotein Test Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on low-density lipoprotein test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for low-density lipoprotein test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Product Type: LDL-C; LDL-P; LDL-B; Other Products
2) By Component: Kits; Reagents; Devices; Other Components
3) By Disease Type: Diabetes; Stroke; Atherosclerosis; Obesity; Dyslipidaemia; Carotid Artery Disease; Peripheral Arterial Disease; Angina; Other Disease Types
4) By Distribution Channel: Direct Tenders; Retail
5) By End User: Hospitals; Clinics; Ambulatory Care; Research Laboratory; Other End Users
Companies Mentioned: Abbott Laboratories; Qiagen N.V.; Randox Laboratories Ltd.; Eurofins Scientific SE; Danaher Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Abbott Laboratories
- Qiagen N.V.
- Randox Laboratories Ltd.
- Eurofins Scientific SE
- Danaher Corporation
- Bio-Rad Laboratories Inc.
- OPKO Health Inc.
- Lincoln Diagnostics LLC
- DiaSorin S.p.A.
- Boster Biological Technology Ltd.
- Rockland Immunochemicals Inc.
- Sekisui Diagnostics LLC
- DiaSys Diagnostic Systems GmbH
- Eurolyser Diagnostica GmbH
- Diazyme Laboratories Inc.
- Cell Biolabs Inc
- Home Access Health Corporation
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- Quest Diagnostics Incorporated
- SpectraCell Laboratories Inc.
- Siemens AG
- Alfa Wassermann Inc.
- Laboratory Corporation of America Holdings
- Merck KGaA
- F Hoffmann-La Roche Ltd.
- Agilent Technologies Inc.
- BioVision Incorporated
- Abcam plc
- BioAssay Systems
- BioChain Institute Inc.
- BioLegend Inc.
- Bioo Scientific LLC
- Enzo Life Sciences Inc.
- GenScript Biotech Corporation
